A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps

• Published in: Journal of managed care & specialty pharmacy Vol. 30; no. 2; pp. 183 - 199
• Main Authors: Jeun, Ki Jin, Kamal, Khalid M., Adhikari, Keyuri, Nolfi, David A., Ashraf, Md. Najeeb, Zacker, Christopher
• Format: Journal Article
• Language: English
• Published: Academy of Managed Care Pharmacy 03-02-2024
• Subjects: Systematic Review
• ISSN: 2376-0540; 2376-1032
• DOI: 10.18553/jmcp.2024.30.2.183

Schizophrenia is a mental condition and is responsible for high burden of care for patients, the health care system, and society. The treatment includes oral antipsychotic medications, which help manage the signs and symptoms of the disease. As patients require long-term treatment, it is important to recognize the reasons for treatment failure. Our study will summarize the existing evidence, which will be useful in assessing the value of new oral antipsychotic drugs for schizophrenia.
Frequent treatment failure in schizophrenia increases health care costs. Our systematic review indicated that treatment with oral antipsychotic treatments (OATs) for schizophrenia is impacted by nonadherence and lack of persistence. The findings illustrate a knowledge gap in humanistic and behavioral outcomes of OATs. By understanding the humanistic, economic, and clinical value of OATs, managed care decision-makers can help facilitate better planning of management policies while addressing unmet needs of patients.